Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects

CONTEXT: Metastatic medullary thyroid carcinoma (MTC) and radioactive iodine–refractory differentiated thyroid carcinoma (RAI-R DTC) have poor prognosis and limited treatment options. Selpercatinib (LOXO-292), a selective kinase inhibitor targeting the RET gene, has shown a 69% to 79% objective resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsang, Venessa, Gill, Anthony, Gild, Matti, Lurie, Brett, Blumer, Lucy, Siddall, Rhonda, Clifton-Bligh, Roderick, Robinson, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387698/
https://www.ncbi.nlm.nih.gov/pubmed/35647935
http://dx.doi.org/10.1210/clinem/dgac337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387698/
https://www.ncbi.nlm.nih.gov/pubmed/35647935
http://dx.doi.org/10.1210/clinem/dgac337

Ejemplares similares